-
Stocks drop, oil climbs after fresh Trump warning to Iran
-
Twins wow Cannes with 'mesmeric' tale of Nigeria's rich
-
New Ebola outbreak in DR Congo: What we know
-
Iran Nobel winner discharged from hospital: supporters
-
Spanish court orders 55 mn euro tax refund to Shakira
-
Ryanair flags Iran war uncertainty as annual profit jumps
-
Hearts have bright future despite Scottish title pain: McInnes
-
Fernandes 'proud' to match Premier League assists record
-
Germany set to miss 2030 climate goal: experts
-
G7 finance chiefs meet to seek common stance on unstable ground
-
Hantavirus-hit cruise ship docks in Rotterdam at voyage end
-
Philippines swears in senators for VP Duterte's impeachment trial
-
Iran's World Cup football team leaves for Turkey: media
-
Hantavirus-hit cruise ship steams towards Rotterdam at voyage end
-
Japan arrests Americans over stunt at baby monkey Punch's zoo
-
Trump says 'clock ticking' for Iran as peace negotiations stall
-
Hong Kong court hears closing arguments in Tiananmen activists' trial
-
World Cup duo Ghana, Cape Verde not among AFCON top seeds
-
African players in Europe: Daring Semenyo wins final for City
-
Kenya's new poaching problem: smuggling Giant Harvester Ants
-
WHO kicks off annual assembly amid hantavirus, Ebola crises
-
S. Korean blockbuster 'Hope' underscores growing film ambition
-
Train driver charged after deadly Bangkok bus collision
-
Angry Chinese table tennis fans demand apology for flag gaffe
-
India's lifeline ferry across strategic archipelago
-
Encroaching world threatens India's last 'uncontacted' tribe
-
India's strategic $9 bn megaport plan for pristine island
-
In Tierra del Fuego, a hunt for the rodent carrier of hantavirus
-
Mitchell leads Cavs past top-seeded Detroit into NBA East finals
-
China's April consumption, factory output growth slowest in years
-
Asian stocks sink, oil rises on US-Iran deadlock
-
Cleveland Cavaliers eliminate top-seeded Detroit from NBA playoffs
-
Who could be the 2026 World Cup's breakout star?
-
Humble PGA champ Rai celebrates English, Indian, Kenyan heritage
-
Hantavirus-hit cruise ship nears end of voyage, to dock in Rotterdam
-
He said, she said, AI said: Wall Street sex scandal rivets and confounds
-
UN General Assembly to take up climate change 'obligations' resolution
-
Four takeaways from Musk vs OpenAI trial
-
Jury to decide fate of Musk's blockbuster suit against OpenAI
-
Frustrated McIlroy drops F-bomb in exchange with PGA heckler
-
Defending champion Palou storms to Indy 500 pole
-
Messi shines as Inter Miami finally win at new stadium
-
Shai Gilgeous-Alexander wins second straight NBA MVP award
-
White House mass prayer event seeks to reclaim US Christian roots
-
International dive group joins Maldives search for missing Italians
-
'Staggering' Iran toll drives up global executions: Amnesty
-
Kingsway Publishes Investor Day Presentation to Company Website
-
Helio Ignites Space Infrastructure IP Race with Patent Filing for Deployable Boom Tech, Positioning as Future Leader in Space-Based Solar Power and Orbital Systems
-
Ryde Appoints Chief Product Officer to Accelerate Platform Innovation and Marketplace Growth
-
XCF Global Highlights Long-Term Growth Drivers for Renewable Fuels as U.S. Biofuel Policy Evolves and SAF Demand Continues to Build
US panel recommends nonprescription use of contraception pill
A US panel of health experts voted Wednesday in favor of making birth control pills available without a prescription, a move backed by reproductive rights advocates especially in the wake of a Supreme Court ruling overturning the national right to abortion.
The independent panel voted unanimously that the benefits of allowing the medicine, Opill, to be sold over the counter, outweighed the risks and would reduce hurdles associated with visiting a doctor that impact lower income groups disproportionately.
"I believe that the efficacy and safety of this birth control form was established over half a century ago," said panelist Jolie Haun of the James A. Haley Veterans' Hospital.
"We now have been presented with ample data demonstrating the effective safe use and benefits for people who want to have access to reproductive autonomy."
The committee's votes are usually accepted by the Food and Drug Administration, which means the pill, which is made by HRA Pharma, might be available without prescription in the coming weeks.
While likely, approval is not assured. FDA scientists highlighted safety concerns, such as the potential impact on people with a history or current diagnosis of breast cancer, or whether they would understand the pill needs to be taken the same time every day to prevent pregnancy.
"There is also concern that some consumers may not consistently use the product correctly on a chronic basis and be at risk for pregnancy, but not recognize that they are pregnant because of the irregular bleeding that would be ascribed to the known side effect," the FDA wrote in a document.
The push for a non-prescription pill has taken on new urgency in light of a Supreme Court decision overturning the constitutional right to abortion, leading to numerous bans and severe restrictions in conservative states.
It has received support from health groups such as the American Medical Association and American College of Obstetricians and Gynecologists.
If the pill is approved, the US would join more than 100 other countries where the pill is available without a prescription, including the UK which requires a consultation with a pharmacist.
Opill is known as a "mini pill" because it contains progestin only.
Another company, Cadence, is in talks with the FDA about making its combination pill, which contains both estrogen and progestin, available over the counter.
P.Martin--AMWN